Ardelyx, Inc. — 2016 Form 10-K Summary
Business context and reporting period
This annual report covers the fiscal year ended December 31, 2016; it is not a standalone fourth-quarter filing. Ardelyx is a clinical-stage biopharmaceutical company developing gut-focused therapies for cardiorenal and gastrointestinal diseases. It had no approved products and generated no product-sales revenue. The filing was signed February 17, 2017.
Financial performance and position
| Metric | FY 2016 | FY 2015 |
|---|---|---|
| Revenue | $0 | $24.0 million |
| Research and development expense | $94.2 million | $39.9 million |
| General and administrative expense | $18.7 million | $13.5 million |
| Operating loss | $112.9 million | $29.4 million |
| Net loss | $112.4 million | $29.6 million |
| Net loss per share, basic and diluted | $2.80 | $1.29 |
| Cash used in operating activities | $92.5 million | $71.8 million |
R&D expense rose 136%, primarily with expanded tenapanor Phase 3 work and manufacturing and development activity across tenapanor, RDX7675 and RDX8940. G&A expense increased 38%, including higher personnel, professional fees and pre-commercialization costs. Revenue disappeared after termination of the AstraZeneca collaboration in 2015; the 2015 comparison included licensing and reimbursed development revenue, not product sales. Profit margins are not meaningful given zero 2016 revenue.
At December 31, 2016, cash and cash equivalents were $74.6 million and short-term investments were $126.2 million, totaling $200.8 million. Current assets were $204.0 million, current liabilities $19.2 million, total liabilities $20.0 million and stockholders’ equity $193.2 million. No debt balance is reported in the supplied financial statements. Management said existing resources should cover projected needs for at least 12 months, while warning that substantial additional capital will be needed and may not be available on acceptable terms. Financing activities provided $191.2 million, largely from public and private equity offerings; shares outstanding increased from 26.0 million to 47.3 million during 2016. The filing reports no off-balance-sheet arrangements.
For the fourth quarter of 2016, revenue was zero, operating expenses were $31.5 million and net loss was $31.3 million, or $0.66 per share.
Material changes and pipeline developments
- Tenapanor was in Phase 3 development for IBS-C and dialysis-related hyperphosphatemia. In February 2017, after year-end but before filing, Ardelyx reported that its first hyperphosphatemia Phase 3 trial met its primary endpoint in the responder population (LS mean difference −0.82 mg/dL; p=0.01). Diarrhea was reported in 39% during treatment; 7.8% discontinued due to diarrhea.
- Two IBS-C Phase 3 trials were fully enrolled with more than 600 patients each. Management expected T3MPO-1 results in mid-2017 and T3MPO-2 results late in 2017, with an NDA submission in 2018 if trials succeeded.
- Management planned to begin a second hyperphosphatemia Phase 3 trial in mid-2017. RDX7675 entered Phase 3 and an onset-of-action trial in late 2016; onset-of-action results were expected in the first half of 2017. Ardelyx anticipated seeking approval through the 505(b)(2) pathway, subject to its availability and trial results.
- RDX8940, a TGR5 agonist being evaluated for NASH and other GI indications, had an IND filed in late 2016. The RDX023 FXR program remained in research, with a lead candidate expected to be selected in 2017.
Outlook, risks and unusual items
Management expected operating losses to increase as clinical development, manufacturing, pre-commercialization and research spending continued. The company planned to build U.S. sales and marketing capabilities for potential products and explore commercial arrangements outside the United States. These are plans, not assured outcomes; the filing gives no revenue or earnings guidance.
- Key risks include clinical-trial failure or delay, regulatory uncertainty, side effects, manufacturing dependence on third parties, competition, reimbursement and pricing pressure, and the need for additional financing. Tenapanor-related GI effects, particularly diarrhea, are a material tolerability consideration.
- Ardelyx warned that Medicare’s planned inclusion of oral ESRD drugs in the dialysis payment bundle beginning in 2025 could reduce prices or reimbursement for relevant products if approved.
- The AstraZeneca collaboration ended in June 2015, returning tenapanor and other NHE3 rights to Ardelyx. In 2015, Ardelyx recognized deferred revenue and made $25 million of payments under the termination arrangement; there was no related collaboration revenue in 2016.
- The financial statements received an unqualified audit opinion. Management concluded disclosure controls and internal control over financial reporting were effective at year-end; the auditor did not provide an internal-control attestation because of the company’s emerging-growth-company exemption.
Important facts for investors to verify
- Review the complete Phase 3 datasets, including endpoints, durability, safety, discontinuations and outcomes outside the tenapanor hyperphosphatemia responder population; distinguish the February 2017 update from FY 2016 results.
- Track actual trial timelines and regulatory requirements for tenapanor, RDX7675 and RDX8940, including whether the 505(b)(2) pathway is available for RDX7675.
- Assess cash burn, investment liquidity and financing needs against management’s 12-month runway estimate, and account for dilution from 2016 equity issuance and outstanding options and warrants.
- Evaluate potential market access, reimbursement, pricing, competition and the effect of ESRD drug bundling; the filing’s patient-market estimates are company estimates, not realized demand.